Qiagen Expands CDx Deal with Tokai; Acquires CTC Assets from AdnaGen | GenomeWeb

NEW YORK (GenomeWeb) – Qiagen and Tokai Pharmaceuticals are expanding their existing agreement to develop and commercialize a companion diagnostic for galeterone, Tokai's late-stage investigational drug for castration-resistant prostate cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.